Functional analysis of PHLDA3, a tumor suppressor gene of neuroendocrine tumors
| Project/Area Number |
26430133
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor biology
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
Ohki Rieko 国立研究開発法人国立がん研究センター, 研究所, 主任研究員 (70356252)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 神経内分泌腫瘍 / PHLDA3 / p53 / Akt |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to clarify the mechanism of neuroendocrine tumor (NET) onset and to obtain results useful for NET treatment / diagnosis. We previosly found that the PHLDA3 gene encodes a novel Akt repressor and has been shown to function as a tumor suppressor gene in NET of lung and pancreas (Cell, Vol. 136 , p. 535-550, 2009, and PNAS, 111 (23), E2404-E2413, 2014). We believe that PHLDA 3 is a tumor suppressor gene of NET derived from various tissues, and we believe that Akt suppression by PHLDA3 plays a central role in NET suppression. Therefore, we believe that inhibitors of the Akt pathway may be effective for patients with LOH of the PHLDA3 gene. Furthermore, LOH of the PHLDA3 gene has a strong correlation with the prognosis of NET patients, and it is possible that LOH diagnosis of the PHLDA3 gene will make it possible to predict patient prognosis. By this research, we believe that we contributed to individualized medical care of NET patients.
|
Report
(4 results)
Research Products
(24 results)
-
-
[Journal Article] A novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells.2016
Author(s)
Ezawa I, Sawai Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Kobayashi Y, Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R.
-
Journal Title
Cancer Sci.
Volume: 印刷中
Issue: 6
Pages: 734-745
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis.2016
Author(s)
Yoshinori Asano, Tatsuya Kawase, Atsushi Okabe, Shuichi Tsutsumi, Hitoshi Ichikawa, Satoko Tatebe, Issay Kitabayashi, Fumio Tashiro, Hideo Namiki, Tadashi Kondo, Kentaro Semba, Hiroyuki Aburatani, Yoichi Taya, Hitoshi Nakagama and Rieko Ohki
-
Journal Title
Scientific Reports
Volume: 6
Issue: 1
Pages: 19174-19174
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
-
-
-
[Journal Article] PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.2014
Author(s)
Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, Minegishi M, Aita Y, Yanai G, Shimizu H, Yachida S, Sakata N, Doi R, Kosuge T, Shimada K, Tycko B,Tsukada T, Kanai Y, Sumi S, Namiki H, Taya Y, Shibata T, Nakagama H.
-
Journal Title
Proc Natl Acad Sci U S A
Volume: Jun 10;111(23)
Issue: 23
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
